Levosimendan suppresses oxidative injury, apoptotic signaling and mitochondrial degeneration in streptozotocin-induced diabetic cardiomyopathy. (2nd January 2016)
- Record Type:
- Journal Article
- Title:
- Levosimendan suppresses oxidative injury, apoptotic signaling and mitochondrial degeneration in streptozotocin-induced diabetic cardiomyopathy. (2nd January 2016)
- Main Title:
- Levosimendan suppresses oxidative injury, apoptotic signaling and mitochondrial degeneration in streptozotocin-induced diabetic cardiomyopathy
- Authors:
- Akhtar, Md Sayeed
Pillai, Krishna Kolappa
Hassan, Quamrul
Ansari, Shahid Husain
Ali, Javed
Akhtar, Mohammed
Najmi, Abul Kalam - Abstract:
- Abstract: Diabetic cardiomyopathy plays a major role in morbidity and mortality among cardiovascular disorder-related complications. This study was designed to explore long-term benefits of Levosimendan (LEVO) along with Ramipril and Insulin. Diabetic cardiomyopathy was induced using streptozotocin (STZ) at the dose of 25 mg/kg/body weight/day for three consecutive days in Wistar rats. Rats were randomly divided into 10 groups and treatments were started after 2 weeks of STZ administration. A gradual but severe hyperglycemia ( §§§ p < 0.001) was observed in all STZ-treated groups except those received insulin (2 U/day). LEVO alone and in combination with Ramipril and Insulin normalized (** p < 0.01) mean arterial pressure and heart rate, restored catalase, superoxide dismutase, malondialdehyde, glutathione level and also attenuated (*** p < 0.001) the raised serum levels of creatine kinase-heart type, lactate dehydrogenase, tumor necrosis factor-alpha, C-reactive protein, and caspase-3 level in heart tissue altered after STZ treatment. Myofibril degeneration, mitochondrial fibrosis and vacuolization occurred after STZ treatment, were also reversed by LEVO in combination with Ramipril and Insulin. The combination of LEVO with Ramipril and Insulin improved hemodynamic functions, maintained cardiac enzymes and ameliorated myofibril damage in diabetic cardiomyopathy.
- Is Part Of:
- Clinical and experimental hypertension. Volume 38:Number 1(2016)
- Journal:
- Clinical and experimental hypertension
- Issue:
- Volume 38:Number 1(2016)
- Issue Display:
- Volume 38, Issue 1 (2016)
- Year:
- 2016
- Volume:
- 38
- Issue:
- 1
- Issue Sort Value:
- 2016-0038-0001-0000
- Page Start:
- 10
- Page End:
- 22
- Publication Date:
- 2016-01-02
- Subjects:
- Cardiomyopathy -- diabetes -- levosimendan -- mitochondrial damage -- oxidative damage -- streptozotocin
Hypertension -- Chemotherapy -- Periodicals
Hypotensive agents -- Periodicals
616.132 - Journal URLs:
- http://informahealthcare.com/loi/ceh ↗
http://informahealthcare.com ↗ - DOI:
- 10.3109/10641963.2015.1047947 ↗
- Languages:
- English
- ISSNs:
- 1064-1963
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.250500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 17121.xml